XOMA Corporation (NASDAQ:XOMA), a leader in the discovery and development of therapeutic antibodies, on 7 may announced its operational highlights and financial results for the first quarter ended March 31, 2014. For the first quarter ended March 31, 2014, XOMA had a net loss of $4.7 million, or $0.04 per share, compared with a net loss of $24.9 million, or $0.30 per share, in the quarter ended March 31, 2013. The net losses in the three months ended March 31, 2014 and 2013, included a $20.0 million gain and $12.8 million loss, respectively, in non-cash revaluations of contingent warrant liabilities, resulting primarily from fluctuations in XOMA’s stock price. XOMA Corp (NASDAQ:XOMA) weekly performance is 16.79%. On last trading day company shares ended up $4.66. Analysts mean target price for the company is $9.13. XOMA Corp (NASDAQ:XOMA) distance from 50-day simple moving average (SMA50) is 9.48%.
Amicus Therapeutics (NASDAQ:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, on 5 may announced financial results for the first quarter ended March 31, 2014. The Company also provided program updates and reiterated full-year 2014 operating expense guidance. Net loss was $15.9 million, or $0.25 per share, compared to a net loss of $17.5 million, or $0.35 per share, for the first quarter 2013. Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares fell -0.34% in last trading session and ended the day on $2.89. FOLD return on assets is -59.30%.Amicus Therapeutics, Inc. (NASDAQ:FOLD) quarterly performance is 32.57%.
On May 30, 2014, CTI BioPharma Corp (NASDAQ:CTIC) changed its name from Cell Therapeutics, Inc. to CTI BioPharma Corp. CTI BioPharma Corp (NASDAQ:CTIC) shares moved up 4.97% in last trading session and was closed at $3.17, while trading in range of $2.97 – $3.22. CTI BioPharma Corp (NASDAQ:CTIC) year to date (YTD) performance is 65.97%.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) is expecting a Food and Drug Administration (FDA) Advisory Committee meeting on June 11-12 to decide whether or not to recommend a Supplemental New Drug Application (sNDA). Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) ended the last trading day at $3.86. Company weekly volatility is calculated as 10.42% and price to cash ratio as 2.86.Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) showed a positive weekly performance of 6.34%.
Analysts at MLV & Co cut their target price on shares of ArQule Inc. (NASDAQ:ARQL) from $3.00 to $1.75 in a research report issued to clients and investors on Monday, Analyst RN reports. The firm currently has a “hold” rating on the stock. MLV & Co ‘s target price indicates a potential upside of 23.24% from the company’s current price. ArQule, Inc. (NASDAQ:ARQL) weekly performance is 4.32%. On last trading day company shares ended up $1.45. Analysts mean target price for the company is $3.25. ArQule, Inc. (NASDAQ:ARQL) distance from 50-day simple moving average (SMA50) is -10.28%.